PROTECT registry (interim analysis) is a TriSalus Life Sciences, Inc. program in thyroid artery embolization. Its next catalyst is a Readout in Q1 2027.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Indication under review: Thyroid artery embolization. Sponsor: TriSalus Life Sciences, Inc. (TLSI). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
The next tracked catalyst for PROTECT registry (interim analysis) is a Readout in Q1 2027.
No FDA decision for PROTECT registry (interim analysis) is in our archive yet.
In our records PROTECT registry (interim analysis) is under review or in development for Thyroid artery embolization.
TriSalus Life Sciences, Inc. (TLSI).
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.